Health
Novo Weight-Loss Drug Saxenda Poses Risk to Bone Health, Study Finds
- Patients who shed pounds also saw decline in bone density
- Research adds to heightened risks from weight-loss drugs
This article is for subscribers only.
New research added to concerns about the downsides of shedding pounds with popular weight-loss shots.
A study done on Saxenda, an older daily weight-loss shot made by Novo Nordisk A/S that’s similar to newer treatments like Ozempic but considered less effective, reported that patients on the drug experienced a decline in bone density in the hips, spine and forearm.